Solventum to Acquire Acera Surgical in $725 Mn Deal to Boost Regenerative Wound-Care Portfolio

The integration is expected to facilitate the use of Restrata products in acute-care settings and may create operational efficiencies by drawing on Solventum’s global network, specialized wound-care sales teams, and experience in negative-pressure wound therapy.

Solventum has signed a definitive agreement to acquire Acera Surgical, a privately held biotech company specializing in fully engineered materials for regenerative wound care, for $725 million in cash, with an additional $125 million for contingent payments.

Founded in 2013 by Matthew MacEwan and Agnès Rey-Giraud, Missouri-based Acera is a bioscience company that has developed and commercialized synthetic solutions for soft-tissue repair, built on its proprietary electrospinning technology platform.

Acera’s flagship product, Restrata, the first electrospun fiber matrix cleared for wound management, is used in regenerative wound care, including in surgical and traumatic wound applications.

Currently, its Restrata products are available in the U.S. and are used in acute-care settings to manage complex, hard-to-heal wounds.

The integration is expected to facilitate the use of Restrata products in acute-care settings and may create operational efficiencies by drawing on Solventum’s global network, specialized wound-care sales teams, and experience in negative-pressure wound therapy.

Commenting on the partnership, Bryan Hanson, CEO of Solventum, said, "Regenerative wound care is an exciting and fast-growing space, and Acera has innovative technology to meet a significant unmet need in acute wound care. Expanding our advanced wound care portfolio into the high-growth synthetic tissue matrices category complements solutions within our existing portfolio and enhances the options our specialized commercial team can provide doctors, nurses, and decision makers within acute care settings.”

Hanson further added, "This is another bold step in our three-phased transformation plan. Our strong financial performance and the strength of our balance sheet have enabled us to move quickly with our first tuck-in acquisition and the announcement of our first share repurchase program. With Solventum's broad market presence, depth of clinical partnerships, and commitment to advancing healthcare, we are confident this acquisition will create significant value for patients, clinicians, and shareholders."

According to reports, Acera is projected to generate approximately $90 million in revenue in 2025.

The transaction is expected to be funded entirely in cash from Solventum’s existing reserves, without the use of new debt or credit facilities. The deal is anticipated to close in the first half of 2026, subject to customary approvals and conditions.

Stay tuned for more such updates on Digital Health News